The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease
about
Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trialsGenetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and SteatohepatitisUnderstanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: The role of genetics.Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents.Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshopEffectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease.The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levelsCurrent pharmacotherapy for treating pediatric nonalcoholic fatty liver disease.Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease.Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.A Review of Recruitment, Adherence and Drop-Out Rates in Omega-3 Polyunsaturated Fatty Acid Supplementation Trials in Children and Adolescents.Meta-analysis reveals a specific association of the PNPLA3 I148M polymorphism with ALT level in adolescents.PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver diseaseTargeting Hepatic Glycerolipid Synthesis and Turnover to Treat Fatty Liver Disease
P2860
Q26748608-353A8869-AAA4-430E-8FB3-435401722A0FQ26798151-40D42699-D8BE-45C4-8E5F-D42628D91723Q33360950-1B379E57-624F-45A1-8F3F-B23EB4099068Q33632921-86543885-AADF-4CD5-9BCE-A562027E4E2CQ33791133-A361CEDE-B6F6-4821-B188-DD0707C892B1Q36154945-FD93227B-FC87-4B03-A548-09159E8A01BFQ37087800-8C2A7387-66CF-4BD1-A5A0-4BD36D6CF574Q37669834-2AA6A86F-2DBE-40CE-A0D8-4C4957CF3A2EQ38249022-2D776BE9-84E8-49D6-B75F-9737C4E2D5BAQ38606360-DDBB6576-35A2-4AD0-84C1-34A69BD502B2Q38675911-38CB0292-628B-4DBC-95A0-A793F53FFEA8Q38845334-AED08F19-19BB-4DDE-A29A-13DE435F55CBQ39295405-F62825A2-2BEF-4844-A20B-9CEEA16403ADQ54212460-E7895D33-BE4D-425E-A7B7-A8063DB86067Q58773505-662714C0-0A19-4A15-895A-4B44AB2873DFQ59049645-D293BD91-8325-445F-86CA-569F6A21BE75
P2860
The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2013
@uk
name
The I148M Variant of PNPLA3 Re ...... -Alcoholic Fatty Liver Disease
@en
The I148M Variant of PNPLA3 Re ...... -Alcoholic Fatty Liver Disease
@nl
type
label
The I148M Variant of PNPLA3 Re ...... -Alcoholic Fatty Liver Disease
@en
The I148M Variant of PNPLA3 Re ...... -Alcoholic Fatty Liver Disease
@nl
prefLabel
The I148M Variant of PNPLA3 Re ...... -Alcoholic Fatty Liver Disease
@en
The I148M Variant of PNPLA3 Re ...... -Alcoholic Fatty Liver Disease
@nl
P50
P356
P1476
The I148M variant of PNPLA3 re ...... -alcoholic fatty liver disease
@en
P2093
Giorgio Bedogni
P304
P356
10.1089/JMF.2013.0043
P577
2013-09-28T00:00:00Z